^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SGLT-2 inhibitor

    Associations

    News

    Trials
    22h
    STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, University of Cologne
    New P3 trial
    2d
    DAPA-ICU: Dapagliflozin for Cardio-renal Protection After ICU Discharge (clinicaltrials.gov)
    P3, N=600, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Jan 2029 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2028 --> Jan 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    3d
    EmFin-Nx: Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT (clinicaltrials.gov)
    P2, N=10, Terminated, Jinling Hospital, China | N=100 --> 10 | Trial completion date: Dec 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Oct 2025; The patient enrollment rate is proceeding too slowly
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3d
    SGLT2i Therapy in Islet Transplantation (SIT) (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, University of Minnesota | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    4d
    Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Yale University
    New P2 trial
    4d
    OPTIMAR: Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, Kirby Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    pitavastatin
    5d
    SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Shanghai Chest Hospital
    New trial
    5d
    The protective effects of dapagliflozin on cisplatin-induced ovarian toxicity via NRF2-HO-1 pathway and TNF-α/Cas3 signaling. (PubMed, Sci Rep)
    DAPA exerts protective effects against CIS-induced ovarian damage by modulating proliferation, cellular stress, inflammation, and apoptotic pathways, as evidenced by the downregulation of PCNA, HSP-70, KISS-1, TNF-α, and CAS-3, and upregulation of NRF2 and HO-1. These findings suggest that DAPA may offer a novel therapeutic approach for preserving ovarian function in patients undergoing chemotherapy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HMOX1 (Heme Oxygenase 1) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen)
    |
    cisplatin
    10d
    The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD (clinicaltrials.gov)
    P3, N=1750, Enrolling by invitation, University Medical Center Groningen | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    10d
    SGLT2i in CRS: Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting | N=60 --> 30
    Enrollment closed • Enrollment change
    11d
    Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) (clinicaltrials.gov)
    P2, N=16, Recruiting, NYU Langone Health | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    13d
    Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease (clinicaltrials.gov)
    P2, N=181, Completed, Shandong Suncadia Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion